SOURCE: ZetrOZ, Inc.

ZetrOZ, Inc.

September 30, 2015 11:07 ET

ZetrOZ, Inc. and the U.S. Army Military Health Command Announce Phase II Grant to Study Sustained Acoustic Medicine (sam®) Technology for Accelerated Wound Healing

Demonstrable Phase I Results Lead to Increased Funding for Phase II

TRUMBULL, CT--(Marketwired - Sep 30, 2015) - ZetrOZ, Inc. was competitively selected for a Phase II award from the U.S. Army Military Health Command (USAMHC) to continue testing sam® (Sustained Acoustic Medicine), an FDA-cleared medical device to accelerate soft-tissue healing, including burns and traumatic wounds. 

As with the Phase I study, which demonstrated that the sam® unit has the ability to stimulate wound healing, work will be performed in a collaboration between ZetrOZ and Professor Stephen Davis, Director of the Pre-Clinical Wound Healing & Infection Research Laboratories in the University of Miami Health System.

"We are very impressed with the results from our initial studies with the sam® unit that showed that this medical device can spur wound healing," said Dr. Davis. "We look forward to our continued investigations in the new Phase II program where we will expand our studies of this innovative device for other types of wounds. These studies may have significant implications for not only wounded military personnel but also for civilians."

"Now that we have validated success for the sam® device to accelerate healing of trauma, our teams will work to develop and deploy innovative wound healing solutions relevant to current military concerns including injuries from IEDs, burns and lacerations," said George K. Lewis Jr., PhD, ZetrOZ President and Chief Scientific Officer. "These latest results open a whole new market opportunity for ZetrOZ in addition to our existing indications for pain reduction and accelerating the natural healing cascade for musculoskeletal injuries, such as tendons, ligaments and muscles."

About ZetrOZ, Inc.
ZetrOZ develops wearable bio-regenerative devices for the delivery of sustained acoustic medicine, a new treatment form. Built on a proprietary miniaturized ultrasound platform designed for the treatment of acute and chronic musculoskeletal conditions, ZetrOZ devices are clinically proven to enhance tissue recovery, accelerate the body's natural healing processes, and relieve pain. Since the company's founding in 2009, ZetrOZ has successfully applied this innovative technology to the development of two products now available on the market: sam Professional System, an FDA approved device, and UltrOZ™ Elite for the maintenance and rehabilitation of equine athletes. For more information, visit www.zetroz.com.

Contact Information